Cargando…
Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade
SIMPLE SUMMARY: Epithelial cancers, such as lung, breast, and colon cancers, have high mortality rates because of their ability to spread across multiple organs in the body. Besides the standard of care which includes chemotherapy and radiotherapy, approaches directed to use patient’s own immune res...
Autores principales: | Sinha, Debottam, Moseley, Philip, Lu, Xuehan, Wright, Quentin, Gabrielli, Brian, Frazer, Ian H., Cruz, Jazmina L. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776741/ https://www.ncbi.nlm.nih.gov/pubmed/36551637 http://dx.doi.org/10.3390/cancers14246150 |
Ejemplares similares
-
Skin-Grafting and Dendritic Cell “Boosted” Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines
por: Zeng, Bijun, et al.
Publicado: (2023) -
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
por: Archilla-Ortega, Adrià, et al.
Publicado: (2022) -
Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure
por: Causer, Andrew, et al.
Publicado: (2023) -
Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013) -
Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype
por: Hao, Xue, et al.
Publicado: (2020)